key: cord-0978536-gctt3gpm
authors: Ma, Aijia; Cheng, Jiangli; Yang, Jing; Dong, Meiling; Liao, Xuelian; Kang, Yan
title: Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients
date: 2020-06-05
journal: Crit Care
DOI: 10.1186/s13054-020-03007-0
sha: 0b212665106e1d48ea4f2e5977c6ed09857485e0
doc_id: 978536
cord_uid: gctt3gpm

ChiCTR, ChiCTR2000029758. Registered 12 February 2020 - Retrospectively registered

Patients diagnosed with severe COVID-19 from 21 hospitals in Sichuan Province between January 16 and March 15 were included in the analysis (ChiCTR2000029758). The maximum value of NLR, PLR, PCT, and CRP during the first 3 days after being diagnosed as severe COVID-19 was included in the analysis. Severe COVID-19 and ARDS were defined according to previous study [4] and Berlin definition [5] , respectively. Multivariate logistic regression analysis and the area under the receiver operating characteristic (ROC) curve were used to analyze the ability of NLR in predicting ARDS.

Of totally 81 patients defined as severe COVID-19, 44 were diagnosed as ARDS. The baseline characteristics of the non-ARDS group and ARDS group are listed in Table 1 . The area under the ROC curve for ARDS was 0.71, 0.591, 0.494, and 0.625 for NLR, PLR, PCT, and CRP, respectively. We used the median as the cutoff value to divide the patients into two groups. The high NLR group (NLR > 9.8) showed a higher incidence of ARDS (P = 0.005) and higher rate of noninvasive (P = 0.002) and invasive (P = 0.048) mechanical ventilation. Further, we defined moderatesevere ARDS as ARDS patients with oxygenation index less than 150. The area under the ROC curve for moderate-severe ARDS was 0.749, 0.660, 0.531, and 0.635 for NLR, PLR, PCT, and CRP, respectively ( Fig. 1) ; the cutoff value of NLR for moderate-severe ARDS is 11.

Our data revealed that NLR could be a valuable biomarker to recognize severe COVID-19 patients with moderate-severe ARDS, which facilitated clinicians to give effective respiratory supporting strategies and quickly find out moderate-severe ARDS patients who are at high indication for V-V ECMO.

Because of the mismatch of the oxygenation and lung function [6] , a comprehensive consideration of immune Data are presented as interquartile range or number (percentage) BMI body mass index, MAP mean arterial pressure, WBC white blood cell, AST aspartate aminotransferase, ALT alanine aminotransferase, PT prothrombin time, APTT activated partial thromboplastin time, NLR neutrophil-to-lymphocyte ratio, ARDS acute respiratory distress syndrome indicators would improve early prediction for COVID-19 patients with "atypical" ARDS [6] . NLR is an extremely common laboratory test wherein the initial NLR value can be used to identify high-risk patients with moderate-severe ARDS, with the optimal threshold value of 11. This biomarker may be helpful in assessing the allocation of respiratory equipment in ICU patients and early assessment of ECMO. However, further clinical studies are needed to evaluate the benefits of NLR in ARDS. 

Preparing for COVID-19: early experience from an intensive care unit in Singapore

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases

Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

Critical care for patients with severe COVID-2019 in Sichuan Province

Acute respiratory distress syndrome: the Berlin definition

COVID-19 Does Not Lead to a "typical" acute respiratory distress syndrome

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

We would like to thank all the medical workers involved in the rescue and the staff for collection of the data in Sichuan. We would like to thank all the investigators of the study of 2019 novel coronavirus pneumonia-infected critically ill patients in Sichuan province (SUNRISE).

Authors' contributions AJM, JLC, MLD, and JY designed the study. MLD and YK participated in the rescue work on the clinical frontline. XLL and YK organized and managed the data and its quality. JLC and AJM collected the data, performed the statistical analysis, and drafted the manuscript with JY. All authors participated in the data interpretation. All authors read the manuscript carefully and approved the final version. 

The datasets used for the analysis in the current study are available from the corresponding author on reasonable request.

The study was approved by the Ethics Committee of the West China Hospital of Sichuan University.

Not applicable.

The authors declare that they have no competing interests.Received: 12 May 2020 Accepted: 20 May 2020